Company Overview of Ardea Biosciences, Inc.
Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Its product candidates include Lesinurad (RDEA594), an inhibitor of the URAT1 kidney transporter, which is in Phase III clinical trials for the treatment of gout; BAY 86-9766 (RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor that is in Phase II clinical trials for the treatment of cancer; and RDEA3170, an URAT1 kidney transporter inhibitor, which is in Phase I clinical trials for the treatment of gout. The company has a development and commercialization license agreement with Bayer Healthcare AG to develop...
4939 Directors Place
San Diego, CA 92121
Key Executives for Ardea Biosciences, Inc.
President and Chief Operating Officer
Senior Vice President of Regulatory Affairs & Development Operations
Senior Vice President of Pharmaceutical Sciences
Vice President of Preclinical Development
Compensation as of Fiscal Year 2014.
Ardea Biosciences, Inc. Key Developments
Astrazeneca and Ardea Biosciences Presents Results from Study of allopurinol
Oct 28 13
AstraZeneca and Ardea Biosciences presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout. The LASSO (Long-term Allopurinol Safety Study evaluating Outcomes in gout patients) study was a multinational, 6-month, open, prospective observational study involving 1,735 patients with gout and was designed to evaluate the safety and efficacy of medically appropriate doses of allopurinol. Results of the LASSO study showed no new safety signals with allopurinol doses of approximately 300mg/day. The study also revealed that at the time of last dose fewer than half (43%) of patients taking allopurinol achieved the target serum uric acid (sUA) level of <6.0 mg/dL, the level recommended by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Specific findings from LASSO include: The study revealed no new safety signals with allopurinol (approximately 300mg/day). There were no cases of allopurinol hypersensitivity syndrome in this study. At the time of last dose 43% of all patients in the study achieved target sUA levels of <6.0 mg/dL. of patients in the study at final doses above 300mg/day, approximately 54% achieved target sUA levels of <6.0 mg/dL.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries